Prevalence of metabolic bone disease among chronic rhinosinusitis patients treated with oral glucocorticoids.
BACKGROUND
The treatment of chronic rhinosinusitis (CRS) often requires chronic or intermittent oral steroid therapy, which has the potential for adverse skeletal effects, including osteoporosis and increased risk of fragility fractures. The purpose of this study was to determine the prevalence of osteopenia/osteoporosis (OP) or low bone density (LBD) in patients with CRS with/without polyposis treated with oral glucocorticoids.


METHODS
Retrospective chart analysis was performed at a tertiary-care rhinology practice. Patients with CRS with/without polyposis evaluated between September 2003 and July 2008 were included if they had (1) previous history of oral steroid usage (> or =5 mg daily for at least 3 months) and (2) previous bone mineral density evaluation.


RESULTS
A total of 197 patients were included with a mean age of 51.1 years (range, 15-79 years). The primary presenting diagnoses included CRS with polyposis in 176 cases (89.3%) and CRS without polyposis in 21 cases (10.7%). Concomitant asthma was present in 161 patients (81.7%). Overall, the prevalence of low bone mass was 38.6%. Among men >50 years of age and postmenopausal women, the prevalence of osteopenia/OP or LBD was 62.5 and 62.2%, respectively. Comparing men >50 years of age and postmenopausal women to their respective younger populations, both had a statistically higher presence of low bone mass (p < 0.0001), with an odds ratio of 10.6 (3.9-28.7) and 34.6 (7.4-161.5), respectively. There was no statistical difference in the presence of bone loss when comparing groups by gender. A multivariable analysis of common comorbidities revealed age to be the only factor associated with increased risk for OP/osteopenia or LBD.


CONCLUSIONS
Patients with CRS with/without polyposis treated with oral steroids who underwent bone density testing were found to have a high prevalence of LBD. High index of suspicion is required to identify at-risk patients and to initiate careful evaluation and treatment to prevent additional bone-related complications.
Rajasekaran
Karthik
K
Chicago Medical School, Rosalind Franklin University of Science and Medicine, North Chicago, IL, USA.
Seth
Rahul
R
Abelson
Abby
A
Batra
Pete S
PS
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D001851:Bone Diseases, Metabolic; D002908:Chronic Disease; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000473:pathology* / Q000601:surgery; D009298:Nasal Polyps; D015995:Prevalence; D012220:Rhinitis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000503:physiopathology; D012307:Risk Factors; D012852:Sinusitis / Q000188:drug therapy / Q000453:epidemiology* / Q000473:pathology / Q000503:physiopathology
D005938:Glucocorticoids